{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:16:30Z","timestamp":1765232190289,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.bcmd.2014.11.001","type":"journal-article","created":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T14:42:51Z","timestamp":1416235371000},"page":"198-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["An analysis of the NIH-supported sickle cell disease research portfolio"],"prefix":"10.1016","volume":"54","author":[{"given":"Nara","family":"Gavini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Keith","family":"Hoots","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George A.","family":"Mensah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjit","family":"Hanspal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2014.11.001_bb0005","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1126\/science.286.5444.1488","article-title":"Perspectives: molecular medicine \u201cSickle cell anemia, a molecular disease\u201d","volume":"286","author":"Strasser","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.bcmd.2014.11.001_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1534\/genetics.167.1.1","article-title":"Sickle-cell anemia hemoglobin: the molecular biology of the first \u201cmolecular disease\u201d\u2014the crucial importance of serendipity","volume":"167","author":"Ingram","year":"2004","journal-title":"Genetics"},{"key":"10.1016\/j.bcmd.2014.11.001_bb0015","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1100\/tsw.2008.157","article-title":"Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches","volume":"8","author":"Steinberg","year":"2008","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.bcmd.2014.11.001_bb0020","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1517\/14656566.2013.783570","article-title":"The acute chest syndrome of sickle cell disease","volume":"14","author":"Desai","year":"2013","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.bcmd.2014.11.001_bb0025","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jpainsymman.2011.06.020","article-title":"Detecting the emergence of chronic pain in sickle cell disease","volume":"43","author":"Hollins","year":"2012","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.bcmd.2014.11.001_bb0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11936-012-0173-x","article-title":"Hemoglobinopathies and stroke: strategies for prevention and treatment","volume":"14","author":"Ali","year":"2012","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"10.1016\/j.bcmd.2014.11.001_bb0035","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/ajh.21838","article-title":"Leg ulcers in sickle cell disease","volume":"85","author":"Minniti","year":"2010","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2014.11.001_bb0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nm.2280","article-title":"Detrimental effects of adenosine signaling in sickle cell disease","volume":"17","author":"Zhang","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcmd.2014.11.001_bb0045","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the U.S.","volume":"38","author":"Hassell","year":"2010","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.bcmd.2014.11.001_bb0050","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/pbc.24176","article-title":"Health-related quality of life in sickle cell disease: past, present, and future","volume":"59","author":"Panepinto","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bcmd.2014.11.001_bb0055","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2174\/1874609810902010012","article-title":"Mitochondria, cellular stress resistance, somatic cell depletion and lifespan","volume":"2","author":"Robb","year":"2009","journal-title":"Curr. Aging Sci."},{"key":"10.1016\/j.bcmd.2014.11.001_bb0060","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/MOH.0b013e328351c35f","article-title":"Clinical management of adult sickle-cell disease","volume":"19","author":"Bartolucci","year":"2012","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.bcmd.2014.11.001_bb0065","first-page":"1084","article-title":"Psychosocial treatments in pain management of sickle cell disease","volume":"102","author":"Edwards","year":"2010","journal-title":"J. Natl. Med. Assoc."},{"key":"10.1016\/j.bcmd.2014.11.001_bb0070","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/ajh.21968","article-title":"Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease","volume":"86","author":"Candrilli","year":"2011","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2014.11.001_bb0075","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pbc.22754","article-title":"Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease","volume":"56","author":"Green","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bcmd.2014.11.001_bb0080","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/pbc.24179","article-title":"Indications and complications of transfusions in sickle cell disease","volume":"59","author":"Smith-Whitley","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bcmd.2014.11.001_bb0085","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/pbc.24758","article-title":"Transcranial Doppler and brain MRI in children with sickle cell disease and high hemoglobin F levels","volume":"61","author":"Asbeutah","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bcmd.2014.11.001_bb0090","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/pbc.22951","article-title":"Effect of transfusion therapy on transcranial Doppler ultrasonography velocities in children with sickle cell disease","volume":"56","author":"Kwiatkowski","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bcmd.2014.11.001_bb0095","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.bbmt.2013.12.564","article-title":"Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells","volume":"20","author":"Kharbanda","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.bcmd.2014.11.001_bb0100","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2146\/ajhp110308","article-title":"Stem cell transplantation for treatment of sickle cell disease: bone marrow versus cord blood transplants","volume":"69","author":"Thompson","year":"2012","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.bcmd.2014.11.001_bb0105","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.trsl.2012.12.011","article-title":"Gene therapy for hemoglobinopathies: progress and challenges","volume":"161","author":"Dong","year":"2013","journal-title":"Transl. Res."},{"key":"10.1016\/j.bcmd.2014.11.001_bb0110","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1182\/blood-2011-02-335554","article-title":"Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease","volume":"118","author":"Zou","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.11.001_bb0115","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/pbc.24180","article-title":"Future directions of sickle cell disease research: the NIH perspective","volume":"59","author":"Hoots","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bcmd.2014.11.001_bb0120","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1182\/blood-2013-05-498311","article-title":"Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies","volume":"122","author":"Manwani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.11.001_bb0125","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.biocel.2006.01.010","article-title":"Sickle cell disease and nitric oxide: a paradigm shift?","volume":"38","author":"Mack","year":"2006","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bcmd.2014.11.001_bb0130","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1128\/MCB.00714-14","article-title":"Fetal globin gene repressors as drug targets for molecular therapies to treat the \u03b2-globinopathies","volume":"34","author":"Suzuki","year":"2014","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bcmd.2014.11.001_bb0135","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1073\/pnas.0711566105","article-title":"Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia","volume":"105","author":"Uda","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107997961400134X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107997961400134X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:30:12Z","timestamp":1761049812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107997961400134X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S107997961400134X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2014.11.001","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An analysis of the NIH-supported sickle cell disease research portfolio","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2014.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}